Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration
Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration
Prion diseases are characterized by accumulation of misfolded protein, gliosis, synaptic dysfunction, and ultimately neuronal loss. This sequence, mirroring key features of Alzheimer disease, is modeled well in ME7 prion disease. We used iTRAQ(TM)/mass spectrometry to compare the hippocampal proteome in control and late-stage ME7 animals. The observed changes associated with reactive glia highlighted some specific proteins that dominate the proteome in late-stage disease. Four of the up-regulated proteins (GFAP, high affinity glutamate transporter (EAAT-2), apo-J (Clusterin), and peroxiredoxin-6) are selectively expressed in astrocytes, but astrocyte proliferation does not contribute to their up-regulation. The known functional role of these proteins suggests this response acts against protein misfolding, excitotoxicity, and neurotoxic reactive oxygen species. A recent convergence of genome-wide association studies and the peripheral measurement of circulating levels of acute phase proteins have focused attention on Clusterin as a modifier of late-stage Alzheimer disease and a biomarker for advanced neurodegeneration. Since ME7 animals allow independent measurement of acute phase proteins in the brain and circulation, we extended our investigation to address whether changes in the brain proteome are detectable in blood. We found no difference in the circulating levels of Clusterin in late-stage prion disease when animals will show behavioral decline, accumulation of misfolded protein, and dramatic synaptic and neuronal loss. This does not preclude an important role of Clusterin in late-stage disease, but it cautions against the assumption that brain levels provide a surrogate peripheral measure for the progression of brain degeneration.
4532-4545
Asuni, Ayodeji A
b1412b1b-9794-4705-aada-aed5d3da038f
Gray, Bryony
be01f5af-8217-4006-a5a3-32286410bc5c
Bailey, Joanne
23e06daf-d78b-4869-94f0-94baeca110fa
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Perry, V Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
O'Connor, Vincent
8021b06c-01a0-4925-9dde-a61c8fe278ca
14 February 2014
Asuni, Ayodeji A
b1412b1b-9794-4705-aada-aed5d3da038f
Gray, Bryony
be01f5af-8217-4006-a5a3-32286410bc5c
Bailey, Joanne
23e06daf-d78b-4869-94f0-94baeca110fa
Skipp, Paul
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Perry, V Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
O'Connor, Vincent
8021b06c-01a0-4925-9dde-a61c8fe278ca
Asuni, Ayodeji A, Gray, Bryony, Bailey, Joanne, Skipp, Paul, Perry, V Hugh and O'Connor, Vincent
(2014)
Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration.
The Journal of Biological Chemistry, 289 (7), .
(doi:10.1074/jbc.M113.502690).
(PMID:24366862)
Abstract
Prion diseases are characterized by accumulation of misfolded protein, gliosis, synaptic dysfunction, and ultimately neuronal loss. This sequence, mirroring key features of Alzheimer disease, is modeled well in ME7 prion disease. We used iTRAQ(TM)/mass spectrometry to compare the hippocampal proteome in control and late-stage ME7 animals. The observed changes associated with reactive glia highlighted some specific proteins that dominate the proteome in late-stage disease. Four of the up-regulated proteins (GFAP, high affinity glutamate transporter (EAAT-2), apo-J (Clusterin), and peroxiredoxin-6) are selectively expressed in astrocytes, but astrocyte proliferation does not contribute to their up-regulation. The known functional role of these proteins suggests this response acts against protein misfolding, excitotoxicity, and neurotoxic reactive oxygen species. A recent convergence of genome-wide association studies and the peripheral measurement of circulating levels of acute phase proteins have focused attention on Clusterin as a modifier of late-stage Alzheimer disease and a biomarker for advanced neurodegeneration. Since ME7 animals allow independent measurement of acute phase proteins in the brain and circulation, we extended our investigation to address whether changes in the brain proteome are detectable in blood. We found no difference in the circulating levels of Clusterin in late-stage prion disease when animals will show behavioral decline, accumulation of misfolded protein, and dramatic synaptic and neuronal loss. This does not preclude an important role of Clusterin in late-stage disease, but it cautions against the assumption that brain levels provide a surrogate peripheral measure for the progression of brain degeneration.
Text
4532.full.pdf
- Version of Record
Available under License Other.
More information
e-pub ahead of print date: 23 December 2013
Published date: 14 February 2014
Organisations:
Biomedicine
Identifiers
Local EPrints ID: 364195
URI: http://eprints.soton.ac.uk/id/eprint/364195
ISSN: 0021-9258
PURE UUID: a7215448-7651-40bf-8f87-79881bdc5d34
Catalogue record
Date deposited: 09 Apr 2014 10:08
Last modified: 15 Mar 2024 03:04
Export record
Altmetrics
Contributors
Author:
Ayodeji A Asuni
Author:
Bryony Gray
Author:
Joanne Bailey
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics